



NDA 20406-S87 and S88  
NDA 21428-S34 and S35

## SUPPLEMENTS APPROVAL

Takeda Global Research & Development Center, Inc.  
Attention: Clint Johansen  
Manager, Global Regulatory Affairs Strategy  
One Takeda Parkway  
Deerfield, Illinois 60015

Dear Mr. Johansen:

Please refer to your Supplemental New Drug Applications (sNDAs) dated April 23<sup>rd</sup>, and May 16<sup>th</sup>, 2018, received, under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for PREVACID (lansoprazole) delayed-release capsules and PREVACID SOLUTAB (lansoprazole) delayed-release orally disintegrating tablets.

We also refer to our letters dated January 24<sup>th</sup>, and February 16<sup>th</sup>, 2018, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for proton pump inhibitors (PPIs). These labeling changes pertain to the following:

- the risk of Fundic Gland Polyps (FGPs) among patients using PPIs for more than one year, and
- the risk of heart valve thickening and bone changes observed in nonclinical data from studies conducted in juvenile rats with lansoprazole, the racemic mixture containing dexlansoprazole.

### **APPROVAL & LABELING**

We have completed our review of these supplemental applications, as amended. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

We note that your June 6, 2018, submissions included final printed labeling (FPL) for your Prescribing Information, Medication Guide and Instructions for Use. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

## **CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert, Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

## **REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Maureen Dewey, Regulatory Project Manager, at (301) 796-0845.

Sincerely,

*{See appended electronic signature page}*

Joyce Korvick, M.D., M.P.H.  
Deputy Director for Safety  
Division of Gastroenterology and Inborn Errors Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research

ENCLOSURE:  
Content of Labeling

-----  
**This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.**  
-----

/s/  
-----

MAUREEN D DEWEY  
06/07/2018

JOYCE A KORVICK  
06/07/2018